Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2100217 | Best Practice & Research Clinical Haematology | 2013 | 4 Pages |
Abstract
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Daniel Weisdorf,